Skip to main content

Table 1 Genotypic resistance results in 23 patients on ART with virological failure (HIV-1 RNA >1000 copies/mL)

From: Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania

ID

Sex

Age

ART regimen: initial (currenta)

Months on ART

Subtype

Viral load

Protease mutations

Reverse transcriptase mutations

34

M

24

ZDV/3TC/NVP (ZDV/3TC/EFV)

42.1

C

434,131

M36I, L63P, H69K, I93L

K103N

84

M

30

d4T/3TC/EFV (d4T/3TC/NVP)

49.1

D

8690

I13V, L33V, M36I, I64V

K103N, M184V

224

M

32

d4T/3TC/NVP

34.7

C

1349

M36I, L63P, H69K, I93L

 

240

M

43

d4T/3TC/EFV (d4T/3TC/NVP)

35.5

CRF01_AE

81,691

I13V, M36I, L63P, H69K

D67N, K70R, K103N, V179T, M184V, K219Q

275

F

41

d4T/3TC/NVP

32.3

D

477,518

I13V, K20R, M36V, L63P, I64V, I93L

G190A

282

F

32

d4T/3TC/NVP

32.4

A

2621

L10I, I13V, M36I, H69K

M184V, Y188C

307

F

35

d4T/3TC/NVP (d4T/3TC/EFV)

31.7

Failed

2301

Failed

Failed

321

F

34

d4T/3TC/NVP

30.4

D

1504

I13V, K20R, M36I, I62V, I64V

Y181C, M184I

366

F

48

d4T/3TC/NVP

28.3

C

3000

M36I, H69K, I93L

K103N, V179T, M184V

401

F

44

d4T/3TC/NVP

28.6

C

2290

M36I, D60E, H69K, I93L

G190A

402

F

40

d4T/3TC/NVP (d4T/3TC/EFV)

28.3

?b

20,500

L10I, I13V, G16E, M36I, H69K

K101P, M184V, G190A, T215F

410

F

45

d4T/3TC/NVP

36.9

D

5990

I13V, L63P, I64V, V77I

K101E, M184V, G190A

473

F

35

d4T/3TC/NVP

27.3

D

3965

I13V, I64V, V77I

M41L, V75I, Y181C, M184V

476

F

19

ZDV/3TC/NVP (d4T/3TC/NVP)

26.5

D

1980

I64V

G190A

516

F

24

d4T/3TC/EFV

24.0

C

419,979

M36I, L63P, H69K, I93L

 

554

F

28

ZDV/3TC/NVP (d4T/3TC/NVP)

24.0

C

1886

K20R, M36I, H69K

 

583

F

30

d4T/3TC/NVP

21.1

CRF01_AE

1432

L10V, G16E, M36IV, H69K

K103N, Y181C, M184V

611

F

33

d4T/3TC/NVP

17.8

C

15,600

M36I, I62V, L63P, H69K, V82I, I93L

K65R, V75I, V108I, Y181C, M184V, L210W

643

F

37

d4T/3TC/NVP

31.3

D

2400

K20R, M36I, I62V, I64M

K70R, Y181C, M184V

749

F

32

d4T/3TC/EFV (d4T/3TC/NVP)

19.0

?c

35,400

I13V, M36I, H69K

K103N, M184V

752

F

35

d4T/3TC/NVP

14.5

A

3101

L10I, M36I, H69K

Y181C, M184V

785

F

26

d4T/3TC/NVP (d4T/3TC/EFV)

14.6

D

3,683,117

I13V, M36I, D60E, I64V

 

982

F

15

d4T/3TC/NVP

8.5

A

76,700

I13V, M36I, L63P, H69K, V82I

V179T, M184V, G190A

  1. aOnly specified if different from initial regimen.bCRF_01AE in the protease and A in the reverse transcriptase gene. cA in the protease and CRF_01AE in the reverse transcriptase gene.
  2. ART, antiretroviral treatment; d4T, stavudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; ZDV, zidovudine.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us